Advertisement
News
Advertisement

Encision Reports Second Quarter of Fiscal Year 2013 Results

Tue, 10/30/2012 - 7:00am
The Associated Press

Encision Inc. (ECIA:PK), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, today announced financial results for its fiscal 2013 second quarter ended September 30, 2012.

The Company posted quarterly product revenue of $2.806 million and quarterly service revenue of $68 thousand for a quarterly net loss of $265 thousand, or $(0.03) per share. These results compare to product revenue of $2.830 million and service revenue of $437 thousand for a net loss of $469 thousand, or $(0.07) per share, in the year-ago quarter. Gross margin was 56 percent compared to 48 percent in the year-ago quarter. In the year-ago quarter, our margin was lower due to a one-time charge of $430 thousand for a voluntary recall of a certain electrode product. Also, the gross profit margin increase from the second quarter of fiscal year 2012 was due, partially, to an increase in gross margin of our disposable scissor inserts.

The Company posted six months product revenue of $5.611 million and six months service revenue of $364 thousand for a six months net loss of $254 thousand, or $(0.03) per share. These results compare to product revenue of $5.664 million and service revenue of $787 thousand for a net loss of $490 thousand, or $(0.04) per share, in the year-ago six months. Gross margin was 56 percent compared to 52 percent in the year-ago six months. In the year-ago six months, our margin was lower due to a one-time charge of $430 thousand for a voluntary recall of a certain electrode product.

"Although we were disappointed that we did not have product revenue growth for the second quarter, we made significant strides to position the company for future growth," said Fred Perner, President and CEO.

"We had expected the decrease in service revenue. In our last quarter's earnings release we announced that, as a result of a project that was phased out by a strategic partner, and unless we obtained another strategic partner or further commitments from existing partners, we anticipated that future service revenue would be significantly reduced as compared to last fiscal year's service revenue." "We continued to use financial resources that were obtained from the issuance of our common stock for sales, marketing, quality programs and product development initiatives to grow future revenue and profitability. During the quarter, in order to obtain broader sales coverage, we changed the composition of our sales management and regions. Also, we introduced quality enhancements to our product line, including an improved disposable foot-activated fixed-tip electrode and an enhanced disposable scissor, the e-EdgeT Scissor, which we began shipping in mid-September. Both of these products are pivotal to our recurring revenue strategy." Encision Inc. designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM@ Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2012 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT:             Mala Ray, Encision Inc., 303-444-2600, mray@encision.com Encision Inc. Condensed Balance Sheets (Amounts in thousands) (Unaudited) September 30, 2012      March 31, 2012 ASSETS Cash and cash equivalents $     558 $    565 Accounts receivable, net 1,085 1,428 Inventories, net 2,472 2,489 Prepaid expenses 107 28     Total current assets 4,222 4,510 Equipment, net 1,654 1,619 Patents, net 276 273 Other assets 7 7     Total assets $ 6,159 $ 6,409 LIABILITIES AND SHAREHOLDERS' EQUITY Accounts payable $   728 $ 1,040 Accrued compensation 284 283 Other accrued liabilities 407 349     Total current liabilities 1,419 1,672 Common stock and additional paid-in capital 21,554 21,297 Accumulated (deficit) (16,814) (16,560)     Total shareholders' equity 4,740 4,737     Total liabilities and shareholders' equity $ 6,159 $  6,409 Encision Inc. Condensed Statements of Operations (Amounts in thousands, except per share information) (Unaudited) Three Months Ended Six Months Ended September 30, 2012 September 30, 2011 September 30, 2012 September 30, 2011 Net revenue:     Product $ 2,806 $ 2,830 $5,611 $ 5,664     Service 68 437 364 787         Total revenue 2,874 3,267 5,975 6,451 Cost of revenue:     Product 1,202 1,525 2,406 2,786     Service 60 176 208 320         Total cost of revenue 1,262 1,701 2,614 3,106 Gross profit 1,612 1,566 3,361 3,345 Operating expenses:     Sales and marketing 945 1,213 1,812 2,250     General and administrative 452 463 980 882     Research and development 478 342 820 673         Total operating expenses 1,875 2,018 3,612 3,805 Operating loss (263) (452) (252) (460) Interest and other expense, net (2) (17) (2) (30) Loss before provision for income taxes (265) (469) (254) (490) Provision for income taxes -- -- -- -- Net loss $  (265) $  (469) $     (254) $  (490) Net loss per share-basic and diluted $ (0.03) $ (0.07) $   (0.03) $ (0.04) Basic and diluted weighted average number of shares 8,210 6,455 8,189 6,455 SOURCE Encision Inc.

-0- 10/30/2012 /Web Site: http://www.encision.com (OTC-PINK:ECIA) / CO: Encision Inc.

ST: Colorado IN: HEA MEQ OTC SU: ERN PRN -- LA01834 -- 0000 10/30/2012 11:00:00 EDT http://www.prnewswire.c

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading